Related Experiment Videos
Acute dystonia induced by lamivudine
Xingwang Song1, Zhiping Hu, Hainan Zhang
1Department of Neurology, Second Xiangya Hospital, Central South University, Changsha, China. sxwlyq@hotmail.com
Clinical Neuropharmacology
|August 3, 2005
Summary
Lamivudine is a common treatment for chronic hepatitis B. This report details two cases of acute dystonic reactions (ADRs) linked to lamivudine, a rare but reversible side effect.
Area of Science:
- Hepatology
- Pharmacology
- Neurology
Background:
- Chronic hepatitis B is a prevalent health concern, particularly in China.
- Lamivudine is a primary therapeutic agent for managing chronic hepatitis B.
- While generally well-tolerated, potential adverse drug reactions require ongoing investigation.
Observation:
- Two cases of acute dystonic reactions (ADRs) were observed in patients undergoing lamivudine treatment.
- Acute dystonic reactions are involuntary muscle contractions, often associated with antipsychotic medications.
- This represents the first documented instance of lamivudine-induced ADRs in English medical literature.
Findings:
- Lamivudine, despite its widespread use and general safety profile, can precipitate acute dystonic reactions.
- These drug-induced ADRs were reversible upon cessation of lamivudine therapy.
- The occurrence of ADRs highlights the importance of monitoring for atypical side effects even with established medications.
Implications:
- Clinicians should be aware of the potential for lamivudine to cause acute dystonic reactions.
- Prompt recognition and discontinuation of lamivudine can lead to the resolution of ADRs.
- Further research may be warranted to elucidate the mechanism underlying lamivudine-induced ADRs and identify at-risk populations.